Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlusEur. J. Cancer 2022 Mar 01;163(2022)79-87, V Atkinson, C Robert, JJ Grob, H Gogas, C Dutriaux, L Demidov, A Gupta, AM Menzies, B Ryll, F Miranda, H Banerjee, M Lau, M Del Vecchio
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.